The association between long noncoding RNA ABHD11-AS1 and malignancy prognosis: a meta-analysis.
LncRNA ABHD11-AS1
Malignancy
Meta-analysis
Prognosis
Review
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
01
03
2024
accepted:
27
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
2
9
2024
Statut:
epublish
Résumé
Accumulating evidence has highlighted that lncRNA ABHD11-AS1 plays an essential role in tumorigenesis and is expected to become a new predictive biomarker and ideal target for cancer therapy, whereas some of their findings are conflicting due to the relatively small sample size of individual studies. Thus, this meta-analysis aimed to quantitatively ascertain the association of ABHD11-AS1 with diverse human malignancies. Eight databases were comprehensively screened for relevant articles on January 1, 2024. The significance of ABHD11-AS1 in malignancies was determined by odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence interval (CI). Subgroup analyses and sensitivity analyses were applied to verify the reliability and robustness of the pooled results. Simultaneously, the GEPIA2021 and UCSC Xena databases were applied to further strengthen the results. Fourteen clinical studies comprising eight kinds of malignancies and 1215 malignancy cases were enrolled into this meta-analysis. The pooled results showed that increased ABHD11-AS1 expression was remarkably associated with lymph node metastasis (OR = 2.73, 95%CI [1.97, 3.77], I Current evidence supports the association of elevated ABHD11-AS1 expression with poor prognosis. Thereby, ABHD11-AS1 may be considered as a promising biomarker to screen cancer and predict malignancy prognosis. Also, there is a necessity for larger-scale multicenter studies with uniform study protocols from different countries to further validate the conclusions.
Sections du résumé
BACKGROUND
BACKGROUND
Accumulating evidence has highlighted that lncRNA ABHD11-AS1 plays an essential role in tumorigenesis and is expected to become a new predictive biomarker and ideal target for cancer therapy, whereas some of their findings are conflicting due to the relatively small sample size of individual studies. Thus, this meta-analysis aimed to quantitatively ascertain the association of ABHD11-AS1 with diverse human malignancies.
METHODS
METHODS
Eight databases were comprehensively screened for relevant articles on January 1, 2024. The significance of ABHD11-AS1 in malignancies was determined by odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence interval (CI). Subgroup analyses and sensitivity analyses were applied to verify the reliability and robustness of the pooled results. Simultaneously, the GEPIA2021 and UCSC Xena databases were applied to further strengthen the results.
RESULTS
RESULTS
Fourteen clinical studies comprising eight kinds of malignancies and 1215 malignancy cases were enrolled into this meta-analysis. The pooled results showed that increased ABHD11-AS1 expression was remarkably associated with lymph node metastasis (OR = 2.73, 95%CI [1.97, 3.77], I
CONCLUSIONS
CONCLUSIONS
Current evidence supports the association of elevated ABHD11-AS1 expression with poor prognosis. Thereby, ABHD11-AS1 may be considered as a promising biomarker to screen cancer and predict malignancy prognosis. Also, there is a necessity for larger-scale multicenter studies with uniform study protocols from different countries to further validate the conclusions.
Identifiants
pubmed: 39223500
doi: 10.1186/s12885-024-12866-7
pii: 10.1186/s12885-024-12866-7
doi:
Substances chimiques
RNA, Long Noncoding
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1083Informations de copyright
© 2024. The Author(s).
Références
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
doi: 10.3322/caac.21834
pubmed: 38572751
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (London, England). 2021;41:1037–48.
doi: 10.1002/cac2.12197
Liu R, Li Q, Li Y, et al. Public preference heterogeneity and predicted uptake rate of upper gastrointestinal cancer screening programs in rural china: discrete choice experiments and latent class analysis. JMIR Public Health Surveill. 2023;9:e42898.
doi: 10.2196/42898
pubmed: 37428530
pmcid: 10366669
Chaji D, Boltong A, Der Vartanian C, et al. Setting the policy agenda for cancer control reform: Australia’s first national cancer control plan. Med J Aust. 2023;219:451–4.
doi: 10.5694/mja2.52120
pubmed: 37925168
Bandini L, Schatz A, Hood V, et al. NCCN policy summit: reducing the cancer burden through prevention and early detection. J Natl Compr Canc Net. 2023;21:910–4.e1.
Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44:2963–97.
doi: 10.1039/C4CS00370E
pubmed: 25739971
Engreitz JM, Ollikainen N, Guttman M. Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol. 2016;17:756–70.
doi: 10.1038/nrm.2016.126
pubmed: 27780979
Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Can Res. 2017;77:3965–81.
doi: 10.1158/0008-5472.CAN-16-2634
Ebrahimi N, Parkhideh S, Samizade S, et al. Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer. Cytokine Growth Factor Rev. 2022;65:61–74.
doi: 10.1016/j.cytogfr.2022.04.003
pubmed: 35597701
Golla U, Sesham K, Dallavalasa S, et al. ABHD11-AS1: An Emerging Long Non-Coding RNA (lncRNA) with Clinical Significance in Human Malignancies. Noncoding RNA. 2022;8:21.
Ramya Devi KT, Karthik D, Mahendran T, et al. Long noncoding RNAs: role and contribution in pancreatic cancer. Transcription. 2021;12:12–27.
doi: 10.1080/21541264.2021.1922071
pubmed: 34036896
pmcid: 8172159
Virgilio E, Giarnieri E, Giovagnoli MR, et al. Long non-coding RNAs in the gastric juice of gastric cancer patients. Pathol Res Pract. 2018;214:1239–46.
doi: 10.1016/j.prp.2018.07.023
pubmed: 30078471
Zhuang X, Tong H, Ding Y, et al. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis. Cell Death Dis. 2019;10:620.
doi: 10.1038/s41419-019-1850-4
pubmed: 31409775
pmcid: 6692390
Wen J, Wang H, Dong T, et al. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway. Cell Prolif. 2019;52:e12569.
doi: 10.1111/cpr.12569
pubmed: 30657221
pmcid: 6495520
Lu H, Zhu C, Chen Y, et al. LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway. Clin Transl Oncol. 2022;24:1124–33.
doi: 10.1007/s12094-021-02753-z
pubmed: 35098448
Lei X, Li L, Duan X. Long non-coding RNA ABHD11-AS1 promotes colorectal cancer development through regulation of miR-133a/SOX4 axis. Biosci Rep. 2018;38:BSR20181386.
Zeng XY, Jiang XY, Yong JH, et al. lncRNA ABHD11-AS1, regulated by the EGFR pathway, contributes to the ovarian cancer tumorigenesis by epigenetically suppressing TIMP2. Cancer Med. 2019;8:7074–85.
doi: 10.1002/cam4.2586
pubmed: 31568657
pmcid: 6853820
Zhou X, Zhong F, Yan Y, et al. Pancreatic cancer cell-derived exosomes promote lymphangiogenesis by downregulating ABHD11-AS1 expression. Cancers (Basel). 2022;14:4612.
Liu Y, Wang LL, Chen S, et al. LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1. J Cell Mol Med. 2018;22:3955–64.
doi: 10.1111/jcmm.13675
pubmed: 29799152
pmcid: 6050509
Zhu C. Long noncoding RNA ABHD11-AS1 promotes the progression of papillary thyroid carcinoma by regulating the MIR-29a/eps15l1 axis. Hebei North University. 2021.
Xin H, Yan Z, Cao J. Long non-coding RNA ABHD11-AS1 boosts gastric cancer development by regulating miR-361-3p/PDPK1 signalling. J Biochem. 2020;168:465–76.
doi: 10.1093/jb/mvaa065
pubmed: 32678870
Qiao X, Lv SX, Qiao Y, et al. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22:8630–9.
pubmed: 30575903
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Researched). 2021;372: n71.
Myung SK. How to review and assess a systematic review and meta-analysis article: a methodological study (secondary publication). J Educ Eval Health Prof. 2023;20:24.
doi: 10.3352/jeehp.2023.20.24
pubmed: 37619974
Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
doi: 10.1186/1745-6215-8-16
pubmed: 17555582
pmcid: 1920534
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
doi: 10.1007/s10654-010-9491-z
pubmed: 20652370
Li C, Tang Z, Zhang W, et al. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021;49:W242–6.
doi: 10.1093/nar/gkab418
pubmed: 34050758
pmcid: 8262695
Lin G, Liu H, Lin J, et al. Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis. Front Oncol. 2023;13:1286610.
doi: 10.3389/fonc.2023.1286610
pubmed: 38130989
pmcid: 10733508
Lin G, Wang Y, Deng L, et al. Prognostic effect of lncRNA BBOX1-AS1 in malignancies: a meta-analysis. Front Genet. 2023;14:1234040.
doi: 10.3389/fgene.2023.1234040
pubmed: 37636267
pmcid: 10453800
Lin G, Liu X, Cong C, et al. Prognostic significance of long noncoding RNA TTN-AS1 in various malignancies. Cancer Reports (Hoboken, NJ). 2023;6:e1876.
doi: 10.1002/cnr2.1876
Review Manager (RevMan). Version 5.3. The Cochrane Collaboration, 2014. Available at revman.cochrane.org.
Yang T, Tian S, Zhao J, et al. LncRNA ABHD11-AS1 activates EGFR signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA. Cell cycle (Georgetown, Tex). 2023;22:2538–51.
Luo J, Jiang Y, Wu L, et al. Long non-coding RNA ABHD11-AS1 promotes colorectal cancer progression and invasion through targeting the integrin subunit alpha 5/focal adhesion kinase/phosphoinositide 3 kinase/Akt signaling pathway. Aging. 2021;13:20179–91.
doi: 10.18632/aging.203342
pubmed: 34375304
pmcid: 8436895
Zhang W, Huang X, Shi J. EZH2-mediated lncRNA ABHD11-AS1 promoter regulates the progression of ovarian cancer by targeting miR-133a-3p. Anticancer Drugs. 2021;32:269–77.
doi: 10.1097/CAD.0000000000001039
pubmed: 33491971
Xue L, Li J, Lin Y, et al. m(6) A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2021;236:2649–58.
doi: 10.1002/jcp.30023
pubmed: 32892348
Zhuang X, Tong H, Ding Y, et al. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis. Cell Death and Disease. 2019;10:620.
Li Z, Wu F, Deng B, et al. LncRNA ABHD11-AS1 promotes proliferation and migration of non-small cell lung cancer cells by regulating STAT1/STAT3 expression. Chin J Clin Oncol. 2019;46:1085–90.
He D, Yue Z, Liu L, et al. Long noncoding RNA ABHD11-AS1 promote cells proliferation and invasion of colorectal cancer via regulating the miR-1254-WNT11 pathway. J Cell Physiol. 2019;234:12070–9.
doi: 10.1002/jcp.27877
pubmed: 30537177
Wen J, Wang H, Dong T, et al. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301–3p/STAT3 axis and PI3K/AKT signalling pathway. Cell Proliferation. 2019;52:e12569.
Lei X, Li L, Duan X. Long non-coding RNA ABHD11-AS1 promotes colorectal cancer development through regulation of miR-133a/SOX4 axis. Bioscience Reports. 2018;38:BSR20181386.
Chen M, Li J, Zhuang C, et al. Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. Oncotarget. 2017;8:28176–86.
doi: 10.18632/oncotarget.14945
pubmed: 28157695
pmcid: 5438641
Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21:22–36.
doi: 10.1038/s41568-020-00306-0
pubmed: 33082563
Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303–22.
doi: 10.1038/s41568-020-0253-2
pubmed: 32300195
Zhou W, Lin Z, Tan W. Deciphering the molecular landscape: integrating single-cell transcriptomics to unravel myofibroblast dynamics and therapeutic targets in clear cell renal cell carcinomas. Front Immunol. 2024;18:1374931.
doi: 10.3389/fimmu.2024.1374931
Liu P, Xing N, Xiahou Z, et al. Unraveling the intricacies of glioblastoma progression and recurrence: insights into the role of NFYB and oxidative phosphorylation at the single-cell level. Front Immunol. 2024;6:1368685.
doi: 10.3389/fimmu.2024.1368685
Fan W, Yang Z, Wu S. Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-seq analyses. Front Immunol. 2024;28:1351287.
Xing J, Cai H, Lin Z, et al. Examining the function of macrophage oxidative stress response and immune system in glioblastoma multiforme through analysis of single-cell transcriptomics. Front Immunol. 2024;11:1288137.
doi: 10.3389/fimmu.2023.1288137
Zhao J, Jiao W, Sui X, et al. Construction of a prognostic model of luteolin for endometrial carcinoma. Am J Transl Res. 2023;15:2122–39.
pubmed: 37056832
pmcid: 10086912
Hou S, Zhang X, Yang J. Long non-coding RNA ABHD11-AS1 facilitates the progression of cervical cancer by competitively binding to miR-330-5p and upregulating MARK2. Exp Cell Res. 2022;410:112929.
doi: 10.1016/j.yexcr.2021.112929
pubmed: 34793775
Zhu D, Hao Q, Qian M, et al. LncRNA ABHD11-AS1 Participates in the Progression of Cervical Carcinoma by Targeting miR-1254 and Is the Key to the Diagnosis and Treatment of Cervical Carcinoma in the Future. J Healthc Eng. 2022;2022:8387458.
doi: 10.1155/2022/8387458
pubmed: 35186240
pmcid: 8853821
Yang T, Tian S, Zhao J, et al. LncRNA ABHD11-AS1 activates EGFR signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA. Cell Cycle. 2023;22:2538–51.
Mehrpour Layeghi S, Arabpour M, Shakoori A, et al. Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer. J Transl Med. 2021;19:364.
doi: 10.1186/s12967-021-03026-7
pubmed: 34446052
pmcid: 8390237